Key takeaways
Vibegron (Gemtesa) and solifenacin (Vesicare) are both medications used to treat overactive bladder (OAB) in adults. However, they belong to different medication classes. Vibegron is a beta-3 adrenergic agonist, while solifenacin is an anticholinergic. Vibegron is taken as a 75 mg tablet once daily, and there is no generic version available. Solifenacin is available as both a tablet and a liquid suspension, with the tablet dose ranging from 5 mg to 10 mg daily, and a generic version is available. Vibegron can cause headaches and cold symptoms, while solifenacin commonly causes dry mouth and constipation. Solifenacin also has more potential side effects, such as dizziness and blurry vision, and it can interact with other medications that affect the nervous system. Vibegron is not recommended for people with severe liver or kidney problems, while solifenacin should be avoided by those with certain eye, stomach, or urinary conditions.
